Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon

PAD’s promise: Same-day discharge after angioplasty

Hospitals that want to add efficiencies to their peripheral artery disease (PAD) programs might take a page from PCI’s playbook. Just as same-day PCI can be feasible and safe for selected patients, same-day discharge after angioplasty may be possible for PAD patients.

FDA adds DVT, PE to apixaban’s approval list

The FDA gave the green light to apixaban as a treatment for deep vein thrombosis (DVT) and pulmonary embolism (PE) and to reduce the risk of DVT and PE recurrence.

Stroke in sickle cell children reduced through blood transfusions

Children receiving blood transfusions for sickle cell anemia saw a 56 percent reduction in the risk for stroke in a study published Aug. 21 in the New England Journal of Medicine.

Atherectomy system recalled due to sheath flaw

The FDA placed a Class I recall on the Diamondback 360 Peripheral Orbital Atherectomy System because the sheath may fracture during use.

Cook Medical enrolls first patient in Zilver PTX Drug Eluting Peripheral Stent clinical study in China

Cook Medical has enrolled the first patient in the clinical study in China of its Zilver PTX Drug Eluting Peripheral Stent. The case was performed by one of the study’s principal investigators, Prof. Peng Liu, M.D., at the China-Japan Friendship Hospital in Beijing.

Thumbnail

Alteplase for stroke: Time, but not age or severity, affects outcomes

Counter to current guidelines in some countries where it is used, intravenous alteplase has been shown to be effective in stroke patients irrespective of age up to 4.5 hours after stroke onset, according to a study published online Aug. 6 in The Lancet. However, for best outcomes, speed was important.

Centralized stroke care reduces mortality, hospital stays

British stroke patients are seeing improvements in areas where full centralization of stroke care has occurred, according to an article published online Aug. 5 in BMJ.

Lombard Medical’s Aorfix receives regulatory approval in Japan for treatment of abdominal aortic aneurysms

Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAA), today announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval, which the Company anticipates receiving in September. Aorfix will be exclusively distributed by Medico's Hirata Inc., one of Japan’s leading suppliers of vascular products with proven expertise in building significant market share for AAA stent grafts. Japan is the world’s second largest, standalone EVAR market.

Displaying 1233 - 1240 of 1638

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.